Conditions: Type 2 Diabetes
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 32
Healthy volunteers: no

Brief summary:
This study will assess the pharmacokinetics of MK-0941 in participants with varying degrees of renal insufficiency.

Detailed description:

Arms:
arm 1: MK-0941 20 mg administered to participants with mild renal insufficiency and type 2 diabetes. arm 2: MK-0941 20 mg administered to participants with moderate renal insufficiency and type 2 diabetes. arm 3: MK-0941 5 mg administered to participants with severe renal insufficiency and type 2 diabetes. arm 4: MK-0941 20 mg administered to age-, gender-, race-, body mass index (BMI)-, and hemoglobin A1C (HbAIc)-matched control subjects with normal renal function and type 2 diabetes. arm 5: MK-0941 5 mg administered to age-, gender-, race-, body mass index (BMI)-, and HbAIc-matched control subjects with normal renal function and type 2 diabetes.

Interventions: intervention 1: MK-0941 20 mg intervention 2: MK-0941 5 mg
Intervention descriptions: intervention 1: Two 10-mg tablets of MK-0941 administered as a single oral dose. intervention 2: MK-0941 administered as one single 5-mg tablet.

Protocol document: